Drug intelligence / Profile preview

NP-18-2

Development stage: Unknown
Lead developer: Nanopharmaceutics
Modality: Small Molecules
Administration: Oral

Overview

NP-18-2 is an orally-bioavailable small molecule drug developed by Nanopharmaceutics, Inc. It is currently in Phase 2 clinical development for Central Nervous System (CNS) disorders. NP-18-2 acts as a selective full agonist of the 5-Hydroxytryptamine receptor 1A (5-HT1A), a ligand and likely agonist for the Sigma-1 receptor, and a selective antagonist of the 5-Hydroxytryptamine receptor 2B (5-HT2B). It also demonstrates selective binding to the Sigma-2 receptor.

Targets

SIGMAR1 (Sigma non-opioid intracellular receptor 1)HTR2B (5-Hydroxytryptamine Receptor 2B)TMEM97 (Sigma-2 receptor complex (TMEM97/PGRMC1))HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on NP-18-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NP-18-2.

Explore the full profile